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INTRODUCTION 
World wide, Breast cancer is by far the most common cancer 
amongst women with an incidence rate more than twice that of colorectal 
cancer and cervical cancer and about three times that of lung cancer.  The 
incidence of breast cancer in India is on the rise and is rapidly becoming 
the number one cancer in females pushing the cervical cancer to second 
place. 
It is reported that one in 22 women in India is likely to suffer from 
breast cancer during her lifetime while the figure is definitely more in 
America where eight being victim of this deadly cancer. The problem 
with preventing breast cancer is that there is no one cause that can be 
pinpointed as being the culprit.  Ofcourse screening for the presence of 
BRCA-1, BRCA-2 mutations is available, though it must be admitted of 
being little use in the Indian context.  
The study has been undertaken to emphasise the importance of 
spreading awareness of the prevalence of this cancer and educating 
women for self breast examination as a part of early screening step. 
Health officials must try & talk about this condition so that women have a 
say in their own health. Screening procedures like mammography, FNAC 
& biopsy, need to be widely publicized so as to what exactly they are 
letting themselves in for. 
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AIM OF THE STUDY 
 
1. To identify the incidence of operable breast cancer, in  Govt. 
Rajaji Hospital, Madurai Medical College, Madurai. 
2. To analyze the clinical staging at the time of admission. 
3. To analyze the age wise incidence of carcinoma breast. 
4. To improve the awareness regarding early detection of breast 
cancer by means of multi modality screening procedures as 
most of the cases in India are locally advanced at the time of 
presentation. 
5. To analyze the preventive measures. 
6. To analyze the multimodality treatment options in operable 
breast cancer. 
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HISTORICAL ASPECTS 
 
The earliest known medical document to man is that what is known 
as the Edwin Smith papyrus.  Edwin Smith was an Egyptologist who 
bought fragments of the documents in London in 1862.   
In ancient Egypt, the history of breast cancer treatment began with 
cauterization of tumors found in the breast with an instrument known as 
the ‘firedrill’.  Though medical practitioners were able to remove these 
tumors, they were unable to stop the disease from taking its course.  
Write the ancient Egyptian doctor of breast cancer, “There is no 
treatment”. 
 
Such was the prevailing wisdom throughout the history of breast 
cancer.  It was not until 17th century in Europe, when the doctors were 
able to comprehend the nature of the disease and they linked the breast 
tumors to the lymph glands in axilla.   
The pioneering work was done by Sir William Stewart Halsted 
who began performing complete mastectomies in 1882 and was popular 
throughout the 20th century until 1970. 
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In 1952, American Cancer Society created the reach to recovery 
program, where a group of women helping other women would go and 
visit patients in hospitals who had just had mastectomies for support and 
to create awareness. 
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ANATOMY OF THE BREAST 
 
15 to 20 lobes of tubuloalveolar glandular tissue, fibrous 
connective tissue that supports it lobe, and the adipose tissue that resides 
in parenchyma between the lobes.  Subcutaneous connective tissue 
typically does not form a distinctive capsule around breast components, 
but, rather, surrounds the gland and extends as septa between the lobes 
and lobules, providing support to the glandular elements.  The deep layer 
of the superficial fascia that lies on the posterior surface of the breast 
fuses with the deep (pectoral) fascia of the chest wall.  A distinct space, 
the retromammary bursa, can be identified anatomically on the posterior 
aspect of the breast and resides between the deep layer of the superficial 
fascia and the deep investing fascia of the pectoralis major and the 
contiguous muscles of the thoracic wall.  The retromammary bursa 
contributes to the mobility of the breast on the chest wall.  Fibrous 
thickenings of supportive connective tissue interdigitate between the 
parenchymal tissue of the breast and extend from the deep layer of the 
superficial fascia to attach to the dermis of the skin.  These suspensory 
structures, known as cooper’s ligaments, insert perpendicular to the 
dermis.  
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SKIN 
• THE AREOLA  : Pigmented , sebaceous glands , Montgomery 
tubercles 
• THE NIPPLE  : 
No glands, circumferential muscle fibres and elastic tissue. 
 
 
 
 
 
 
 
 
 STRUCTURAL ANATOMY 
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MICROSTRUCTURE 
• Tubulo alveolar glands 
• Fibrous connective tissue stroma 
• Interlobular adipose tissue 
                            
STROMA 
INTRALOBULAR STROMA- Connective tissue stroma has loose 
texture allowing rapid expansion of secretory tissue during pregnancy 
- INTERLOBULAR STROMA- suspensory ligaments (of Astley 
Cooper) are condensations of fibrous tissue from ducts to dermis, 
more in the upper quadrants  
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ARTERIAL SUPPLY 
• Lateral thoracic branch of 2nd part of axillary artery 
• Medial mammary branches of internal thoracic artery 
• Superior thoracic branch of axillary artery 
• Lateral branches of 2nd,3rd,4th posterior intercostal arteries  
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VENOUS DRAINAGE 
 
• Circulus venosus - venous plexus deep to the areola 
• From this plexus two sets of veins are formed : 
1.  superficial set- ends in internal thoracic vein 
2.  deep set - ends in internal thoracic, axillary and posterior intercostal 
veins 
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LYMPHATIC DRAINAGE 
• AXILLARY NODES- 75 % of lymph drain into axillary nodes 
• PARASTERNAL NODES- remaining 25% lymph into parasternal 
nodes. 
• GROUPS –        ANATOMISTS - 5       
SURGEONS   - 6             
• lateral or axillary vein group         
• external mammary or  pectoral or medial group 
• scapular  or posterior group 
• central group 
• subclavicular or apical group 
• interpectoral or rotter group  
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LEVELS OF AXILLARY NODES 
 
LEVEL 1 NODES: 
    lateral to the lateral border of pectoralis minor muscle external 
mammary, scapular, axillary vein and central  groups 
LEVEL 2 NODES: 
    under the pectoralis minor  muscle   central, axillary vein group 
LEVEL 3 NODES:   
    subclavicular nodes medial to medial border of pectoralis minor and 
first rib 
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ANATOMY OF AXILLARY TENT 
• BASE- Axillary fascia 
• APEX- aperture that extends into the posterior triangle of neck 
through CERVICO AXILLARY CANAL  
• ANTERIOR WALL – Pectoralis muscles and fascia    
• POSTERIOR WALL- Subscapularis , Teresmajor, Lattismus 
Dorsi. 
• LATERAL WALL- Bicipital groove 
• MEDIAL WALL- Serratus anterior  
• CLAVIPECTORAL FASCIA: 
•  upper portion –COSTOCOROCOID MEMBRANE pierced by   
cephalic vein, lateral pectoral nerve, branches of thoraco acromial 
artery                                             
• Middle portion- pectoralis minor pierced by median pectoral nerve 
• Lower portion –CORACO AXILLARY ligament                
HALSTEAD LIGAMENT- medial side of clavicle to the first rib 
• AXILLARY ARTERY: 3 PORTIONS identification of the 
branches of 2nd portion is essential.                                             
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CARCINOMA BREAST 
REVIEW OF LITERATURE 
RISK FACTORS  
Age 
 Carcinoma of the breast is extremely rare before the age of 20 
years but, thereafter, the incidence steadily rises so that by the age of 90 
years nearly 20% of women are affected.   
Gender  
 Female sex carries increased risk.  Less than 0.5% of patients with 
breast cancer are males. 
Genetic  
 It occurs more commonly in women with a family history of breast 
cancer than in the general population.  Breast cancer related to a specific 
mutation accounts for about 5% of breast cancers. Yet it has far reaching 
repercussions in terms of counselling and attempted prevention in these 
women.   
Breast cancer syndromes 
1. Li-Fraumeni syndrome 
2. Cowden’s disease 
3. Ataxia telangiectasia 
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Chromosomal Abnormalities 
1. BRCA -1  gene mutation – Chromosome 17q 
2. BRCA-2  gene mutation – Chromosome 13 q 
3. HER-2  mutation (rbB2, transmembrane growth factor) 
    4.  P 53 mutation 
Diet 
 Dietary factors may play a part in its causation, because breast 
cancer so commonly affects women in the developed world,.  There is 
some evidence that there is a link between diets low in phyto-oestrogens 
and carcinoma breast.  A high intake of alcohol is associated with an 
increased risk of developing breast cancer. 
Endocrine. 
 Breast cancer is commoner in nulliparous women and breast 
feeding in particular appears to be protective. Also protective is having a 
first child at an early age, especially if associated with late menarche and 
early menopause.  It is known that in post menopausal women, breast 
cancer is more common in the obese.  This is thought to be because of an 
increased conversion of steroid hormones to oestradiol in the body fat.  
The role of exogenous hormones, in particular the oral contraceptive pill 
and HRT, in the development of breast cancer is more controversial, but 
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it can be said with some authority that for most women the benefits of 
these treatments will far outweigh the small putative risk. 
Pathology 
 Breast cancer may arise from the epithelium of the duct system 
anywhere from the nipple end of major lactiferous ducts to the terminal 
duct unit, which is in the breast lobule.  The disease may be entirely in 
situ, an increasingly common phenomenon with the advent of breast 
cancer screening, or may be invasive cancer.  The degree of 
differentiation of the tumour is usually described by three grades: well 
differentiated, moderately differentiated or poorly differentiated.  
Commonly, a numerical grading system based on the scoring of three 
individual factors (nuclear pleomorphism, tubule formation and mitotic 
rate) is used, with grade III cancers roughly equating to the poorly 
differentiated group.  
 Previously, descriptive terms were used to classify breast cancer 
(scirrhous, meaning woody, or medullary, meaning brain like). More 
recently, histological descriptions have been used.  These have been 
shown to have clinical correlations in the way the tumour behaves and are 
likely to be used for the near future.  However, with the increasing 
application of molecular markers, there will be a change and it is likely 
that much more information about an individual tumour will be routinely 
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reported, such as its likelihood of metastasis and to which therapeutic 
agents it will be susceptible.  
Current nomenclature  
 Ductal carcinoma is the most common variant, but lobular 
carcinoma occurs in up to 15% of cases.  There are subtypes of lobular 
cancer including the classical type, which carries a better prognosis than 
the pleomorphic type.  Occasionally, the picture may be mixed with both 
ductal and lobular features.  Rarer histological variants, usually carrying a 
better prognosis, included colloid carcinoma, whose cells produce 
abundant mucin, medullary carcinoma with solid sheets of large cells 
often associated with a marked lymphocytic reaction and tubular 
carcinoma.  Invasive lobular carcinoma is commonly multifocal and/or 
bilateral. Cases detected via the screening programme are often smaller, 
better differentiated and of special type than those presenting to the 
symptomatic service.  
 Inflammatory carcinoma is a fortunately rare, highly aggressive 
cancer that presents as a painful, swollen breast, which is warm with 
cutaneous oedema.  This is due to blockage of the subdermal lymphatics 
with carcinoma cells. Inflammatory cancer usually involves at least one-
third of the breast and may mimic a breast abscess. A biopsy will confirm 
the diagnosis and show undifferentiated carcinoma cells.  It used to be 
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rapidly fatal with surgery only hastening the end, but with aggressive 
chemotherapy and radiotherapy with salvage surgery, the prognosis has 
improved considerably.  
 In situ carcinoma is preinvasive cancer that has not breached the 
epithelial basement membrane.  This was previously a rare, usually 
asymptomatic finding in breast biopsy specimens, but is becoming 
increasingly common owing to the advent of mammographic screening: it 
now accounts for over 20% of cancers detected by screening in the UK.  
In situ carcinoma may be ductal (DCIS) or lobular (LCIS), the latter often 
multifocal and bilateral. Both are markers for the later development of 
invasive cancer, which will go on to develop in at least 20% of cases.  
Although mastectomy is curative, this is over treatment in many cases 
and the best treatment for in situ carcinoma is the subject of a number of 
clinical trials.  DCIS may be classified by the Van Nuys system, which 
combines the patient’s age, type of DCIS and presence of 
microcalcification, extent of resection margin and size of disease.  
Patients with a high score benefit from radiotherapy after excision, 
whereas those of low grade, who are completely excised, need no further 
treatment.   
 Staining for oestrogen and progesterone receptor (ER and PR) is 
now considered routine, as their presence will indicate the use of adjuvant 
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hormonal therapy with tamoxifen.  Increasingly, tumours are stained for  
C-erbB2 (a growth factor receptor), as patients can be treated with the 
monoclonal antibody against this receptor if they relapse. 
 The pathologist is an important member of the breast cancer team 
and will increasingly help decide which adjuvant therapies will be 
appropriate.  
Paget’s disease of the nipple  
 Paget’s disease of the nipple (Fig.55.27a. and b.) is a superficial 
manifestation of an underlying breast carcinoma.  It presents as an 
eczema-like condition of the nipple and areola, which persists despite 
local treatment.  The nipple is eroded slowly and eventually disappear.  If 
left, the underlying carcinoma will sooner or later become clinically 
evident.  Nipple eczema should be biopsed if there is any doubt about its 
cause.  Microscopically, Paget’s diseases is characterized by the presence 
of large, ovoid cells with abundant, clear, pale-staining cytoplasm in the 
Malpighian layer of the epidermis. 
THE SPREAD OF BREAST CANCER. 
Local spread 
 The tumour increases in size and invades other portions of the 
breast.  It tends to involve the skin and to penetrate the pectoral muscles 
and even the chest wall.  
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Lymphatic metastasis 
 Lymphatic metastasis occurs primarily to the axillary lymph nodes 
and to the internal mammary chain of lymph nodes.  The site of the 
tumour within the breast does not dictate which nodes will be involved, 
for example medial tumours spread just as readily to the axillary nodes as 
do lateral tumours. The involvement of lymph nodes is not just a 
chronological event in the evolution of the carcinoma, but rather a marker 
for the metastatic potential of the tumour. Involvement of supraclavicular 
nodes and of any contralateral lymph nodes represents advanced disease.  
Spread by the bloodstream. 
 It is by this route that skeletal metastases occur, although the initial 
spread may be via the lymphatic system.  In order of frequency, the 
lumbar vertebrae, femur, thoracic vertebrae, rib and skull are affected and 
these deposits are generally osteolytic.  Metastases may also commonly 
occur in the liver, lung and brain and occasionally, the adrenal glands and 
ovaries, but have been described in most body sites.  
Clinical presentation  
 Although any portion of the breast, including the axillary tail, may 
be involved, breast cancer is found most frequently in the upper, outer 
quadrant.  Most breast cancers will present as a hard lump, which may be 
associated with in drawing of the nipple.  As the disease advances locally 
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there may be skin involvement with peau d’orange or frank ulceration 
and fixation to the chest wall.  This is described as cancer-en-cuirasse.  
About 5% of breast cancers in the UK will present with either locally 
advanced disease or symptoms of metastatic disease.  This figure is 
nearer 20% in the developing world.  These patients must then undergo a 
staging evaluation so that the full extent of their disease can be 
ascertained.  This will include a careful clinical examination, chest 
radiograph, serum alkaline phosphatase and gamma-glutamine 
transaminase (GGT), with liver ultrasound if these are abnormal and an 
isotope bone scan.  This is important for both prognosis and treatment: a 
patient with widespread visceral metastases may obtain an increased 
length and quality of survival from systemic hormone or chemotherapy, 
but she is not likely to benefit from surgery as she will die from her 
metastases before local disease become becomes a problem.  In contrast, 
patients with relatively small (less than 5cm in diameter) tumours 
confined to the breast and ipsilateral lymph nodes rarely need staging 
beyond a good clinical examination as the pick-up rate for distant 
metastases is so low. Currently, a chest radiograph, full blood count and 
liver function tests are all that are recommended for screening for patients 
with early-stage breast cancer.  
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Peau d’orange 
 Peau d’orange is due to cutaneous lymphatic oedema, where the 
infiltrated skin is tethered by the sweat ducts, it cannot swell,  leading to 
an appearance like orange skin.  Occasionally the same phenomenon is 
seen over a chronic abscess. 
 Late oedema of the arm is a troublesome complication of breast 
cancer treatment, fortunately seen less often now that radical axillary 
dissection and radiotherapy are rarely combined.  However, it does still 
occur occasionally after either modality of treatment alone and appears at 
any time from months to years after treatment.  There is usually no 
precipitating cause but recurrent tumour should be excluded as neoplastic 
infiltration of the axilla can cause arm swelling due to both lymphatic and 
venous blockage.  This neoplastic infiltration is often painful due to 
brachial plexus nerve involvement. 
 An oedematous limb is susceptible to bacterial infections following 
quite minor trauma and these require vigorous antibiotic treatment.  
Antibiotics may need to be given for much longer than is normal and 
patients at risk of infection should have antibiotics readily available in 
order to start treatment promptly.  Treatment of late oedema is difficult 
but limb elevation, elastic arm stockings and pneumatic compression 
devices can be useful. 
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Cancer-en-cuirasse. 
 The skin of the chest is infiltrated with carcinoma and has been 
likened to a coat.  It may be associated with a grossly swollen arm.  This 
usually occurs in cases with local recurrence after mastectomy, and 
occasionally is seen to follow the distribution of irradiation to the chest 
wall.  The condition may respond to palliative systemic treatment, but 
prognosis in terms of survival is poor.  
 
Lymphangiosarcoma  
Lymphangiosarcoma is a rare complication of lymphoedema with 
an onset many years following the original treatment.  It takes the form of 
multiple subcutaneous nodules in the upper limb and must be 
distinguished from recurrent carcinoma of the breast.  The prognosis is 
poor but some cases respond to cytotoxic therapy or irradiation.  
Interscapulothoracic forequarter amputation is sometimes indicated.  
 
Staging of breast cancer  
 There are two traditional systems of classification for breast 
carcinoma, which predominantly rely on clinical staging of the disease. 
These are the Manchester system and the International Union Against 
Cancer, TNM (tumour, nodes, metastases)staging system.  
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Tx - Primary tumor cannot be assessed 
T0 - No evidence of primary tumor 
Tis - Carcinoma in situ 
Tis - (DCIS) Ductal carcinoma in situ 
Tis - (LCIS) lobular carcinoma in situ 
Tis - (Paget’s) Paget’s disease of the nipple with no tumour 
 
 
 
 
 
 
Tis (Paget’s) is defined as Paget’s disease of the nipple with no tumor 
T1 - Tumor 2cm or less in greatest dimension 
 
 
 
 
 
T1 mic (m) or T1 mic (3) 
T1 mic is defined as microinvasion 0.1 cm or less in greatest 
dimension.  The presence of multiple tumor foci of microinvasion 
should be noted in parentheses 
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- T1 is defined as a tumor 2 cm or less in greatest dimension.   
- T1a is defined as tumor more than 0.1 cm but less than 0.5 cm in 
greatest dimension :   
- T1b is defiend as a tumor more than 0.5 cm but not more than 1 
cm in greatest dimension :   
- T1c is defined as tumor more than 1 cm but not more than 2cm 
in greatest dimension. 
 
 
 
 
 
 
 
T2 (above dotted line) is defined as tumor more than 2 cm but not 
more than 5 cm in greatest dimension and T3 (below dotted line) is 
defiend as tumor more than 5 cm in greatest dimension. 
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T4 -  Tumour of any size with direct extension to 
a) Chest wall or 
b) Skin, only as described below 
 
 
 
 
 
 
 
T4a is defined as a tumor of any size with direct extension to chest 
wall, not including pectoralis muscle 
 
 
 
 
 
 
 
A -  T4b, illustrated here as satellite skin nodules, is defined as 
edema (including peau d’ orange) or ulceration of the skin of 
the breast, or satellite skin nodules confined to the same breast. 
B -   T4b illustrated here as edema (including peau d’orange) 
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T4 c is defined as both T4a and T4b 
 
 
 
 
T4d, inflammatory carcinoma 
 
Regional Lymph Node (N) : 
Nx - Regional lymph nodes cannot be assessed (eg 
 Previously removed) 
N0 - No regional lymph node metastasis 
 
 
 
 
 
 
 
N1 is defined as metastasis in movable ipsilateral axillary node (s) 
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N2a is defined as metastasis in ipsilateral axillary lymph nodes fixed 
to one another (matted) or to other structures 
 
 
 
 
 
N2b is defined as metastasis only in clinically apparent ipsilateral 
internal mammary nodes and in the absence of clinically evident 
axillary lymph node metastasis. 
 
 
 
 
 
 
N3a metastasis in ipsilateral infraclavicular lymph nodes without 
axillary or internal mammary lymph node involvement 
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N3b metastasis in ipsilateral internal mammary lymphnode and 
axillary lymph nodes 
 
 
 
 
 
 
N3c is defined as metastasis in ipsilateral supraclavicular  
lymph nodes 
Mx   - Distant metastases cannot be assessed 
  
M0   - No evidence of distant metastases 
 
M1 - Presence of distant metastases 
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STAGE GROUPING 
 
 
 T0 T1 T2 T3 T4 
No  I    
N1  IIa IIb  IIIb 
N2  IIIa    
N3   IIIc   
M1  IV    
 
Prognosis of breast cancer  
 The best indicators of likely prognosis in breast cancer are still 
tumour size and lymph node status.  However, it is realised that some 
large tumours will remain confined to the breast for decades, whereas 
some very small tumours are incurable at diagnosis.  Hence the prognosis 
of a cancer depends not on its chronological age but on its invasive and 
metastatic potential.  Although prognosis broadly correlates with stage, 
other factors also influence prognosis and should be assessed, for 
example the Nottingham Prognostic Index includes not only tumour size 
and lymph node status but also tumour grade.  This has been validated in 
many centres and consists of a score given by the formulae I= (0.2x size) 
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+ grade + nodes.  The size is in centimeters, the grade is on a 1-3 score 
and the nodes are also scored on 1-3 where a score of one indicates no 
nodal involvement, two indicates on the there nodes involved.  Based on 
the overall index, patients can be divided into an excellent prognosis 
group, a moderate prognosis group and a poor prognosis group.  The 
chance of dying from breast cancer in the first group is so low that many 
patients do not require additional treatment. 
 Equally, the use of adjuvant systemic therapy is decided not only 
on tumour size and lymph node status but also biological measures such 
as oestrogen receptor status, patient age and menopausa status. 
Tamoxifen can be recommended irrespective of clinicopathological 
variable if the patient is hormone receptor positive.  
 Thus, as we gain more knowledge of the biological variables that 
affect prognosis, it becomes increasingly clear that it is these factors 
(Histological grade of the tumour, hormone receptor status, measures of 
tumour proliferation such as S-phase fraction and thymidine labeling 
index, growth factor analysis and oncogene or oncogene product 
measurements.), rather than anatomical mapping, which influence 
outcome and treatment.  Perhaps a more pragmatic approach would be to 
classify patients according to the treatment that they require.  
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Pragmatic classification for breast cancer 
Group Approximate 
5–year survival 
Example Treatment 
‘very-low-risk 
primary breast 
cancer 
>90% Screen-detected DCIS, 
tubular or special types
Local 
‘Low-risk primary 
breast cancer 
70-90% Node negative with 
favourable histology 
Locoregional 
with/without 
systemic 
‘High-risk primary 
breast cancer 
<70% Node positive with 
unfavourable histology
Locoregional 
with systemic 
Locally advanced <30% Large primary or 
inflammatory 
Primary systemic 
Metastatic - - Primary systemic 
 
Early Breast cancer :   Stage I,  IIA & IIB 
 All patients should be treated using a protocol based multi – 
modality treatment plan.  The primary modality for treating EBC is 
surgery augmented by adjuvant radiation therapy to improve loco 
regional control of the disease and systemic therapy in the form of 
chemotherapy and hormone therapy for improving systemic control and 
overall survival of the patients. 
 The two components of primary surgical treatment of the EBC – 
Management of the breast primary and the axilla – almost always go hand 
in hand.  With better understanding of the disease process recognition of 
fact that the survival of breast cancer patients does not depend on the 
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radicality of the breast surgical procedure and use of evidence based 
medicine tools to test appropriateness of lesser radical surgical procedure 
in management of EBC, the world has seen a dramatic and progressive 
conservation in management of the breast primary as well as the axilla. 
 While standard surgical procedure for breast primary has changed 
from a radical mastectomy to a wide local excision in appropriate patients 
over past 4 decades or so, the management of axilla has seen a paradigm 
shift from a routine complex axillary dissection in all patients to 
avoidance of axillary dissection by use of sentinel lymph node biopsy 
(SLNB) in selected patients with clinically impalpable axillary 
lymphnode in whom the SLNB is reported non metastatic on histology. 
Breast Surgery options for EBC :  Whole Breast removal options 
1. Modified radical mastectomy with a routine axillary clearance 
2. Total mastectomy and SLNB, proceed to axillary clearance if 
sentinel lymph node is reported metastatic on histology. 
BREAST CONSERVATION OPTIONS : 
1. Wide local excision with 1 cm clearance all around and 
occasionally quadrantectomy with routine axillary clearance. 
2. WLE or quadrantectomy with SLNB, proceed to axillary 
clearance if sentinel lymph node is reported metastatic on 
histology. 
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INDICATIONS FOR BCT : 
1. Choice of the patient 
2. Size of the tumor < 4 cm / mammographically detected lesions 
3. Clinically negative axillary nodes or N1   
4. Well differentiated tumors 
Contraindications for BCT : 
Absolute : 
1. Persistent positive margin > 2 times 
2. Previous RT (poor skin tolerance) 
3. Multicentricity 
4. Pregnancy 
Relative : 
1. Collagen vascular disease 
2. Tumor breast ratio 
3. Poorly differentiated tumors 
 
Radiotherapy in BCT : 
 A post operative irradiation to the breast with / without boost to the 
tumor bed is a must following breast conservation surgery.  Radiotherapy 
may be 
1. Whole breast irradiation with a dose of 45-50 Gy given as   2 
Gy/day, 5 days a week over 5 weeks & boost to region of tumor bed.  
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Radiation boost to tumor bed can be delivered either with interstitial 
implants or using electron or photon beam external radiation. 
2. Accelearated partial breast Irradiation : 
 Post lumpectomy RT exerts its maximal effect on eradicating 
residual disease in the region of tumour bed and that areas of occult 
disease in the remainder of the breast is of little practical significance. 
 This hypothesis provides basis for the use of accelerated partial 
breast irradiation which is a NEW treatment option.  In this technique, 
larger daily doses of RT is administered only to portion of breast 
containing primary tumor over 4-5 days, in contrast to 5 week course 
required for whole breast irradiation, by Brachytherapy (Interstitial, 
intracavitary), limited EBRT, intra operative limited RT. 
Recurrence after BCT : 
 The local recurrence rates after lumpectomy and radiation therapy 
are now less than 5% at 10 years in many large centres.  The types of 
recurrences are 
1. True Recurrence :  Recurrences at or near primary site (with in 
boosted region) 
2. Marginal Miss :   Adjacent to boosted region 
3. Elsewhere :  Occuring at a distance from original tumor and 
prerumably representing a new primary. 
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The choice between a mastectomy procedure and BCT rate on variable 
factors and all patients desirous of and  who do not have any 
contraindications for BCT and radiation therapy should be offered Breast 
conservation surgery.  Yet mastectomy continues to be the commonest 
form of curative surgical procedure due to various reasons including low 
acceptability on patient’s part and lack of adequate radiotherapy and 
pathology infrastructure, training and skills at most centres in India and 
other developing countries. 
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Management Protocol for early breast cancer 
Stage I,  IIA,  II B 
 
Breast conservation      Breast Conservation 
Indicated candidates          contraindicated candidates 
 
 
               MRM/Mastectomy 
          +  SLNB 
Local excision of lump with 
1 cm margin all around                      Observation 
 
                    +    L.nodes -ve 
  
            SLNB  
 by separate incision              L.nodes +ve 
 
 
      Axillary dissection 
 
RT – whole breast irradiation with a                               Adjuvant chemotherapy 
Dose of 45-50Gy with boost to region         adjuvant hormonal  
Of tumor bed (10-16 Gy)        therapy if tumor size  
                   is  > 0.5 cm 
  
       
 
Adjuvant chemotherapy and hormonal 
Therapy if tumor size is > 0.5 cm 
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LOCALLY ADVANCED BREAST CANCER 
The definition of LABC has evolved from that of Haagensen and Stout, 
to encompass a wide spectrum of clinical presentations : 
¾ Large tumors (> 5 cm) 
¾ Extensive regional lymph node involvement 
¾ Direct involvement of the underlying chest wall or skin with edema 
(including peau d’orange) or ulceration or satellite skin nodules 
confined to the same breast.  Other discrete skin changes, such as 
dimpling or nipple retraction, may occur in T1-3 disease; they do 
not constitute evidence of a locally advanced tumor. 
¾ Tumors considered inoperable but without distant metastasis 
(including involvement of the supraclavicular lymph nodes) 
¾ Inflammatory breast cancer (IBC) 
 All T and N permutations included in stage II B, III or IV 
comprised many distinct substage possibilities.  The presence of T4 or N3 
or regional M1 lesions would result in inclusion in the stage IIIB / IV 
unresectable subcategory.  Most of the patients with either T3 or N2 but 
without T4, N3 or regional M1 lesions, are included in the stage II / IIIA 
or operable subcategory. LABC also includes T2 tumors that are too large 
in proportion to the size of the breast.   The clinical diagnosis of 
LABC is usually not difficult.  Patients uniformly present with a large 
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breast mass.  Other symptoms often reported are edema, redness, nipple 
retraction, pain, skin dimpling, an axillary mass and breast ulceration.  
Most physical findings are obvious upon inspection or palpation.  
However, in younger women, some tumors infiltrate the breast diffusely 
and a discrete mass is difficult to palpate.  More than 75% of patients 
have clinically palpable axillary and / or supraclavicular adenopathy, and 
65% - 90% of patients have pathologically confirmed lymphnode 
metastasis ; > 50% have more than four nodes involved.  Most of the 
LABCs are operable ; only 25%-30% are diagnosed at an inoperable 
stage. 
 A core needle biopsy is quite effective in establishing the diagnosis 
and also allowing tumor samples to be obtained for hormone receptors, 
DNA studies and other biomarkers.   
Appropriate staging procedures should be performed in patients 
with LABC since the probability of distant metastases is high. 
Approximately 20% of these patients, appropriately staged, have 
detectable distant metastases at the time of diagnosis.   
 After the physical examination and bilateral mammogram, the 
following additional tests are recommended ; a biochemical profile, 
including tests of liver and renal function, and calcium level ; chest x ray; 
bone scans ; radio graphs of areas that appear to be abnormal on the bone 
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scan ; computed tomography of the liver and an ultrasonography of the 
breast and regional lymph nodes to precisely assess the tumor extent.  
The importance of an accurate initial assessment of the extent of primary 
tumor burden cannot be overemphasized since the efficacy of subsequent 
local treatment will depend mostly on this initial assessment. 
1. Patients with LABC are more prone to develop occult 
micrometastases elsewhere at the time of presentation. 
2. In view of extensive skin involvement, local recurrence is 
common and adequate skin clearance is not possible. 
Hence all patients with LABC are immediately exposed to systemic 
therapy (Neo adjuvant). 
Principles of Neo-adjuvant Treatment : 
1. Decreases the incidence of local recurrence 
2. Controls the micrometastases at the outset. 
3. Helps to assess the response of individual patients to systemic 
chemotherapy in vivo which is a strong prognostic factor. 
4. Causes shrinkage of tumor thereby facilitating skin closure. 
Following Neo-adjuvant treatment patients are assessed using RECIST 
criteria. 
(Response Evaluation Criteria In Solid Tumors) based on clinical & 
radiological examination and the response is classified as 
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CR  -  Complete resolution clinically and radiologically which  
   persist for more than 4 weeks 
PR  -  >  50% response clinically and image wise 
NR -   <  50% response 
 Because physical examination and mammography do not 
adequately predict the pathologic response to neoadjuvant chemotherapy, 
alternative imaging methods have been developed to attempt to more 
accurately predict a pathologic response and to improve breast 
conservation rates.  MRI is one promising modality and appears to 
correlate well with pathologic response. 
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LABC 
TREATMENT PATHWAYS 
Clinically stage III A,  IIIB & IIIC Breast Cancer 
 
WORK UP 
 
Operable Stage III A    Inoperable Stage III A &  
        Stage IIIB 
       Neoadjuvant therapy  
        (3-4 cycles) 
 
      Response  No response 
 
     Operable  Inoperable  
 
 Surgery       Individualised  
               therapy 
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Operable LABC :  
 Patients with stage III A disease should undergo modified radical 
mastectomy (MRM), and adjuvant chemotherapy and locoregional 
radiotherapy if feasible.  They may be managed with MRM followed by 
chemotherapy and locoregional radiotherapy, or chemotherapy first 
followed by MRM and locoregional radiotherapy.  Breast conserving 
surgery is currently not a standard approach. 
 In the trails that compared preoperative chemotherapy with 
chemotherapy administered post operatively, the proportion of women 
with tumours greater than 5 cm in diameter ranged from 5% to 27%. 
Patients with operable stage III disease who desire to preserve their breast 
should be made aware that BCS is currently not a standard approach and 
is generally not recommended. 
 
Choice of chemotherapy : 
 Chemotherapy should contain an anthracycline.  Acceptable 
regimens are 6 cycles of FAC, CAF, CEF or FEC.   
 
Inoperable LABC : 
 Patients with stage IIIB or IIIC disease, including those with 
inflammatory breast cancer and those with isolated ipsilateral internal 
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mammary or supraclavicular lymph-node involvement, should be treated 
with primary anthracycline – based chemotherapy. 
Acceptable chemotherapy regimens are FAC, CAF, CEF or FEC. 
CHEMOTHERAPY  COMBINATIONS 
FAC  chemotherapy : 
 5 – Fluorouracil  500 mg / m2  IV days  1 & 8 or days 1 & 4 
        Doxorubicin 50 mg/m2 IV day 1 (or by 72 hrs continuous  
  infusion) 
 Cyclophosphamide 500 mg/m2  IV day 1 cycled every 21 days  
  for 6 cycles 
CAF chemotherapy : 
 Cyclophosphamide 100 mg/m2 PO days 1-14 
 Doxorubicin  30 mg/m2 IV days 1 & 8 
 5-Fluorouracil 500 mg/m2 IV days 1 & 8 cycled every 28 days  
  for 6 cycles 
AC chemotherapy : 
 Doxorubicin 60 mg /m2 IV day 1 
 Cyclophosphamide 600 mg/ m2  IV day 1 
 Cycled every 21 days for 4 cycles 
FEC chemotherapy : 
 Cyclophosphamide 75mg/ m2  PO days 1-14 
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 Epirubicin 60 mg / m2 IV days 1 & 8 
 5 – Fluorouracil 500 mg / m2 IV days 1 & 8 
 With cotrimoxazole support. Cycled every 28 days for 6 cycles 
Preoperative radiation therapy was often able to convert an 
inoperable breast cancer to an operable one.  Preoperative radiation 
therapy did not seem to differ from post operative radiation in providing 
additional locoregional control. A combination of surgery and radiation 
therapy provided the maximum chance for locoregional control over high 
dose radiation therapy or surgery alone. 
 When locoregional radiotherapy is delivered following MRM for 
locally advanced disease, radiation should be delivered to the chest wall, 
supraclavicular and axillary nodes.  Whether treatment to the internal 
mammary nodes is required is unclear. The recommended dose of 
radiation is 50 Gy in 25 fractions or equivalent. 
• Patients with stage III B disease who respond to chemotherapy 
should receive  surgery plus locoregional radiotherapy 
• The locoregional management of patients with stage III C disease 
who respond to chemotherapy is unclear and should be 
individualized. 
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• Patients whose disease remains inoperable following chemotherapy 
should receive locoregional radiotherapy and subsequent surgery if 
feasible. 
Patients who are treated primarily with radiotherapy should be 
given tumouricidal doses to areas of bulk disease (60-66Gy in 30 to 33 
fractions or equivalent )  Higher doses of radiation (70 Gy in 35 fractions 
by external beam or brachytherapy) to areas of bulk disease may be 
considered for patients if surgery is felt not to be an option and if 
tolerance of critical organs permits.  Two case series have reported a 
doseresponse relation with higher doses of radiation that resulted in 
decreased rates of local recurrence. 
For the patient who has a partial or complete response to 
chemotherapy and whose lesion is converted to an operable state, the next 
manoeuvre is typically mastectomy to debulk gross disease, to facilitate 
local-regional control, and to allow for the pathologic assessment of 
response.  For patients with a complete or partial response, the optimal 
chemotherapy to use after local-regional treatment is uncertain.  
Specifically, it is not clear whether to continue the same chemotherapy as 
before after local-regional treatment or whether a cross-resistant 
chemotherapeutic  regimen is indicated.  The ASCO  guidelines 
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recommend postmastectomy radiation treatment, in general, for those 
patients who require a mastectomy 
For the patient whose tumor remains inoperable after first-line 
systemic chemotherapy, the options are to proceed with second-line 
chemotherapy or to deliver preoperative radiation treatment. One major 
goal of treatment is to attempt to convert the lesion from an inoperable to 
an operable state, because patients without local – regional control have 
substantially diminished quality of life. 
Inflammatory Breast Cancer : 
Inflammatory breast cancer is a distinct clinical subtype of locally 
advanced breast cancer, with a particularly aggressive behavior and poor 
prognosis.  Clinically, inflammatory breast cancer typically presents with 
the rapid onset of breast erythema, warmth, and edema, often without a 
discrete underlying mass.  The swelling of the breast can be quite 
pronounced, producing significant tenderness.  Although histologic proof 
of malignancy is critical prior to treatment of IBC, documenting dermal 
lymphatic permeation is not critical in establishing the diagnosis of IBC. 
Bonnier et al classified patients into three groups according to 
clinical and histopathological features. 
Group A included patients with typical inflammatory breast cancer 
(diffuse enlargement of the breast, often no palpable tumour, redness and 
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oedema of the skin) Ipsilateral enlargement of the axillary nodes was 
often detected and emboli of carcinoma cells in the subdermal lymphatics 
were often found. 
Group  B  included patients with occult inflammatory breast 
cancer, in which the presence of tumour emboli in dermal lymphatics was 
not associated with inflammatory symptoms and signs. 
Group C  included patients with pseudo-inflammatory breast 
cancer. Symptoms were similar to those of groupA.  However a tumour 
mass was more readily palpable and the sub-dermal lymphatics were 
never involved  Furthermore, the axillary nodes were rarely involved. 
Neglected locally advanced breast cancer can develop secondary 
inflammatory characteristics, but should be distinguished from primary 
inflammatory carcinoma as these secondary inflammatory breast cancers 
may follow a more indolent course and can be treated as other locally 
advanced breast carcinomas.  Three biological features make 
inflammatory breast cancer a unique clinical entity: 
(1) Rapidity of progression  
(2) High angiogenic and angioinvasive capability 
(3) Aggressive behavior from inception. 
 
 
 48
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 49
Advanced Breast Cancer :  Stage IV 
 Metastatic spread of breast cancer is invariably associated with 
death from the disease.  The median survival from the manifestation of 
metastases is about 3 years in most reported series.  Metastatic disease 
can be discovered is less than 5% to 10% of the newly diagnosed cases of 
breast cancer.  In most cases, metastasis can be detected during 
surveillance after the course of initial therapy for the primary cancer.  
About 75% of patients who develop metastatic disease after initial 
treatment of primary will do so within 5 years of diagnosis of the primary 
tumor.  While managing the metastatic breast cancer, all efforts should be 
made to provide adequate palliation and to extend the survival wherever 
possible. 
 The most common sites of distant mets are bone (49% to 60%), 
lung (15-20%), pleura (10%-18%). Soft tissues (7% to 15%) and liver 
(5% - 15%).  Routine history and careful physical examination can detect 
91.8% of all recurrences. 
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Prognostic factors in Advanced Breast Cancer : 
1. Tumor biology (Grade, ER, PR status, Her 2 µ status) 
2. Performance status 
3. Cancer related symptoms 
4. Site of recurrence 
5. Number of sites of recurrence 
6. Prior adjuvant therapy 
7. Disease free interval 
8. Prior therapy for metastatic disease 
9. Response / duration of treatment with prior therapy for 
metastatic disease. 
 
No. Good Prognosis Bad prognosis 
1. Patient who received less 
therapy 
Heavily treated patients with  
2. Long disease free interval 
since diagnosis 
shorter interval since treatment 
3. Soft tissue / bone mets Visceral mets 
4. Fewer symptoms Greater symptomatology 
5. Better performance status - 
6. ER, PR  positive - 
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MANAGEMENT PROTOCOL 
Advanced Carcinoma Breast 
 
ER, PR  +ve      ER, PR,  -ve 
 
Hormonal therapy     Chemotherapy 
 
Refractory to hormonal therapy 
      Her-2µ  +ve      Her-2µ  -ve 
 
        CT+Trastuzumab Chemotherapy 
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Surveillance following initial management of breast cancer : 
American Society of clinical Oncology Guidelines: Survelliance for  
Breast Cancer Follow-upo 
 
Test 
History, eliciting of symptoms, 
Physical examination 
Breast self examination 
Mammography (contralateral &  
Ipsilateral) 
Pelvic examination 
Complete blood counts, liver 
chemistry, 
Serum Tumour markers (CA 19-3, 
CEA) 
X-ray chest, Bone scan 
USG of liver, CT scan of chest,  
 
Abdomen and pelvis 
Frequency 
Every 3-6mg X 3y, 
Every 6-12 mo X2y, then annually 
Monthly 
Annually 
 
Annually 
Not recommended 
 
Not recommended 
Not  recommended 
 
Not recommended 
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Hormonal therapy : 
The various modalities of endocrine manipulation available in the 
management of advanced breast cancer include. 
 
Selective Estrogen Receptor Modulators:  
1.Tamoxifen 
  2.Torimefen 
Androgens  :  Fluoxymesterone 
Progrestins :  Megestrol acetate 
    Medroxyprogesterone aceate 
High dose Estrogens 
Aromatase inhibitors: 1st generation: Aminoglutethemide  
   2nd generation : Formestane (Type 1), Fadrzole 
   3rd generation: Exemestane (Type1), Anastrazole, 
   Letrozole, Vorozole 
Steroidal Antiestrogens:  Fulvestrant 
 LHRH agonists: Leuprolide, Goserelin 
Gland ablation:  
Surgical (open/laparoscopic): chemical; radiation  
  Ovary; Pituitary; Adrenals  
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Targeted therapy – recent advances : 
 Advances in molecular biology are reaching therapeutic application 
on several fronts.  One example is the targeting of the HER-2 tyrosine 
kinase receptor.  Trastuzumb (Herceptin, Genentech, San Francisco) is a 
humanized monoclonal antibody that binds to HER-2 with great affinity, 
resulting in growth arrest of HER-2 over expressing cancer cells.  The 
addition of trastuzumab to AC and paclitaxel improves time to 
progression, response rates, and overall survival for patients with 
advanced breast cancer over expressing HER-2.  Monoclonal antibodies 
are large molecules and are likely to be more effective in the adjuvant 
setting.  Randomized trials that integrate trastuzumab in combination with 
chemotherapy are under way. 
 
 
 
 
 
 
 
 
 
 55
MATERIALS AND METHODS 
 
 277 cases of carcinoma breast admitted in Govt. Rajaji Hospital, 
Madurai Medical College, Madurai during the period of December 2007 
to November 2009 were studied out of which 4 were male patients and 
they were excluded from the study. 
 A detailed history has been taken and thorough general 
examination was made and cases were studied as per the proforma 
attached. 
 These patients were analysed according to age, clinical 
Presentation, stage of the disease, menopausal status. 
 A special attention was given to LABC since it formed the major 
bulk of my study group where neo adjuvant therapy was given.  
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RESULTS 
Age Distribution 
 
Age in Years 
Cases 
No. % 
Up to 30  18 6.6 
31-40  72 26.4 
41-50 86 31.5 
51-60 65 23.8 
61-70 27 9.9 
> 70 5 1.8 
Total 273 100 
 
 In this group, maximum number of patients were found in the age 
group of 41-50 years whereas the incidence was less in the extremes of 
age. 
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Stage at the time of Presentation 
Type of Breast Cancer Cases 
No. % 
Early breast cancer 
I & II 
119 43.6 
Locally advanced breast 
cancer 
III (O) + III A IO - ) + 
III A (IO) + III B 
(Down staged) + III B (IO) 
118 43.2 
Advanced Carcinoma breast 
IV 
36 13.2 
Total 273 100 
 
 In this study group, 43.6% belong to early breast cancer and an 
equivalent percentage to locally advanced breast cancer.  13.2% of 
patients were in the advanced stage. 
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Menopausal Status 
 
Menopausal Status 
Cases 
No. % 
Pre menopausal 144 52.9 
Post menopausal 129 47.3 
Total 273 100 
 
 In this study, 52.9% were pre menopausal and 47.3% were post 
menopausal. 
Age wise distribution of Staging 
 
Age group 
Staging 
I II III A 
(o) 
III A 
(IO) O
III A 
IO 
III B III B 
IO 
IV Total
Up to 30  7 1 3 3 0 0 2 2 18 
31-40  14 20 10 8 0 6 5 9 72 
41-50 2 41 24 4 1 3 3 8 86 
51-60 2 22 20 9 1 0 3 8 65 
61-70 1 9 8 2 0 0 1 6 27 
> 70 0 0 2 0 0 0 0 3 5 
Total 26 93 67 26 2 9 14 36 273 
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Incidence of operability 
 
Staging  
Cases 
No. % 
Operable Carcinoma 
I 
II 
III A (O) 
III A (IO) – (O) 
III B 
Total Operable 
 
26 
93 
67 
26 
9 
221 
 
9.5 
34.1 
24.5 
9.5 
3.3 
81 
Inoperable 
III A  (IO) 
III B (IO) 
IV 
Total  inoperable 
 
2 
14 
36 
52 
 
0.7 
5.1 
13.2 
19 
Total 273 100 
 
 In this study group, 81% of the patients  were found to be operable.  
This includes patients with LABC who are initially inoperable but 
downstaged and became operable.  19% of the patients were inoperable. 
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Comparison between our study and SEER study of  
National Cancer Institute,  
US.  (2002 – 2006) 
 
Stage of Breast Cancer Our study SEER Study 
I 9.5% 60% 
II & III 77.2% 33% 
IV 13.2% 5% 
 
 
Age at Diagnosis Our study SEER Study 
Under 20 years 0 % 0 % 
20 – 34 yrs 11% 1.9% 
35 – 44 yrs 28.2% 10.5% 
45-54 yrs 28.9% 22.5% 
55 – 64 yrs 22.3% 23.7% 
> 65 yrs 9.5% 41.3% 
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DISCUSSION 
 273 cases of Carcinoma breast, admitted in Government Rajaji 
Hospital, Madurai are presented in this dissertation.  The maximum age 
incidence of Carcinoma breast in the study group has been 41-50 years of 
age. 
 In this study group, about 9.5% of the patients were with stage I 
disease.  This when compared to the SEER study of National Cancer 
Institute,US was very low where stage I accounted for 60%.  This reflects 
the need for spreading the awareness among women regarding self breast 
examination and utilizing screening programme. 
 Locally advanced breast cancer accounted for 77.2% where as it is 
only 33% in SEER study which again reinforces the need for 
improvement in health education.  Stage IV disease accounted for 13.2% 
and 5% in my study and SEER study respectively. 
 About 68.2% of patients in the study group were operable initially 
at the time of admission itself. 
 18.6% of patients were inoperable at the time of admission, out of 
which 12.8% of patients were downstaged and became operable and 5.9% 
of patients remained inoperable even after downstaging. 
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Down staging was done with 3 cycles of CAF regimen and in some 
cases with chemo RT and response was assessed both clinically and 
radiogically with mammogram. 
All patients were assessed preoperatively by clinical examination, 
biopsy and for metastatic work up chest x-ray and  USG abdomen were 
done. 
All operable patients underwent modified radical mastectomy and 
followed by adjuvant therapy with either chemotherapy or radiotherapy 
or both and hormonal therapy. 
About 81.2% of patients were operable including those patients 
who were downstaged. 
To conclude one of the important factors of fight against breast 
cancer is breast cancer awareness.  The more knowledge known about the 
disease and the more done to check for early warning signs, the better 
chance for survival.  Research and development continues to be done so 
that one day we can say the history of breast cancer is over. 
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CONCLUSION 
 The incidence of stage I breast cancer in this study group is only 
9.5% whereas it is 60% in the SEER study of National Cancer Institute 
(NCI) of United States.  LABC accounted for 77.2% in the study group 
whereas its only 33% in SEER study.  The significance of this conclusion 
is that what cases are classified at a specific instance as LABC once 
belonged to the category of early breast cancer and subsequently evolved 
into LABC due to either patient’s lack of awareness about the disease or 
inappropriate interventions or aggressive tumor biology.  Thus as 
prevention is always better than cure it is recommended that the follow up 
measures can be adopted to address this problem. 
1. Improving Health education regarding self breast examination 
2. Screening mammography 
3. General education about early symptoms of the disease and access 
to medical facilities are important in diminishing breast cancer 
incidence. 
4. Identification of high risk population and specific management 
5. Surveillance when family history is positive for breast cancer.  
Metastatic work up is mandatory. 
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S.No Name AGE GROUP Age Sex IP No Side TNM Stage O/IO
TYPE 
OF BC STAGE Treatment given
Menopausal 
status
1 RAJALAXMI 4 52 F 51028 R T2 N1 M0 A 1 II 2 MRM® POST
2 POUN 3 45 F 54442 R T4b N2 M1 B 3 IV 8 Pal. Mast PRE
3 FARITHA BAGAM 3 50 F 60721 L T3 N1 M0 A 2 III a 3 MRM (L) POST
4 PARVATHY 4 52 F 56985 L T2 N2 M0 A 1 II 2 MRM POST
5 LAKSHMI 4 55 F 59489 R T3 N2 M0 A 2 III A(IO)-->O 4 MRM neo-adj-chemo POST
6 POORANAM 4 55 F 52450 B/L T2 N1 A 1 II 2 B/L MRM POST
7 MANJU 3 45 F 62285 L T3 N1 M0 A 2 III A 3 MRM PRE
8 VIJAYALAXMI 3 44 F 63232 R T1 N1 M0 A 1 II 2 MRM PRE
9 KAMATCHI 5 70 F 63246 L T4b N3c M1 B 3 IV 8 Pal.chemo POST
10 SUNDARAM 2 40 F 62743 R Tx N0 M0 A 1 I 1 MRM PRE
11 KATHAMMAL 5 70 F 66329 L T4b N2 M1 B 3 IV 8 Pal. Mast + chemo  POST
12 MEENATCHI 5 63 F 66207 L T3 N1 M0 A 2 III A 3 MRM POST
13 VIJAYA 2 34 F 63454 L T3 N2 M0 A 2 III B(IO)-->O 4 Pal.  chemo  PRE
14 CHINNAMMAL 4 55 F 72558 R T2 N1 M0 A 1 II 2 MRM POST
15 GIRIJA 3 50 F 79016 R T3 N0 M0 A 1 II 2 MRM POST
16 SUSEELA 3 50 F 80906 L T3 N2 M0 A 2 III A(IO)-->O 4 MRM neo-adjchemo POST
17 DHANAPACKIYAM 3 48 F 79297 R T3 N1 M0 A 2 III a 3 MRM POST
18 PONUTHAI 2 40 F 87406 R T3 N2 M1 B 3 IV 8 Pal. chemo +Hormona PRE
19 GANGA 4 55 F 91199 R T3 N1 M0 A 2 III A 3 MRM POST
20 PAPPAIYAMMAL 3 50 F 98320 R T3 N1 M0 A 2 III a 3 MRM POST
21 MARIAMMAL 1 27 F 97768 L Tx N0 M0 A 1 I 1 MRM PRE
22 PANDIAMMAL 2 40 F 99127 L T2 N1 M0 A 1 II 2 MRM PRE
23 PANCHAMMAL 4 58 F 28014 L T4b N2 M1 B 3 IV 8 Pal. Mast + chemo  POST
24 RAKKU 4 60 F 25749 L T3 N2 M0 A 2 III A(IO)-->O 4 MRM POST
25 SULOCHANA 5 62 F 33651 R T3 N0 M0 A 1 II 2 MRM POST
26 CHANDRA 3 50 F 31232 R T3 N0 M0 A 1 II 2 MRM POST
27 SUBBULAXMI 4 55 F 75129 R T3 N1 M0 A 2 III A 3 MRM POST
28 PAPU BEGAM 3 45 F 77861 R T4 N2 M0 A 2 III B(O) 6 MRM PRE
29 KALIYAMMAL 4 55 F 77807 L T2 N2 M0 A 2 III A(IO)-->O 4 MRM POST
Staging
S.No Name AGE GROUP Age Sex IP No Side TNM Stage O/IO
TYPE 
OF BC STAGE Treatment given
Menopausal 
statusStaging
30 RAMALAXMI 4 60 F 76989 R T3 N1 M0 A 2 III A(IO)-->O 4 MRM POST
31 VIJAYALAXMI 4 60 F 73098 R Tx N0 M0 A 1 I 1 MRM POST
32 AMALAPUSPAM 3 47 F 74240 L T3 N1 M0 A 2 III A 3 MRM PRE
33 LAKSHMI 3 50 F 72239 L T2 N1 M0 A 1 II 2 MRM PRE
34 MUTHULAXMI 3 50 F 64106 R T3 N0 M0 A 1 II 2 MRM POST
35 PAPPU 4 60 F 61426 L T3 N1 M0 A 2 III A 3 MRM POST
36 MOOKAMMAL 3 43 F 55927 L T2 N1 M0 A 1 II 2 MRM PRE
37 NAGALAXMI 3 42 F 51789 L T1 N1 M0 A 1 II 2 MRM PRE
38 AROCKIAMMAL 4 60 F 649244 L T3 N1 M0 A 2 III A 3 MRM POST
39 DHANAM 2 40 F 647069 L T2 N1 M0 A 1 II 2 MRM PRE
40 ANNALAKSHMI 4 52 F 48102 R T2 N1 M0 A 1 II 2 MRM PRE
41 POTTIAMMAL 2 40 F 46602 R T4 N2 M0 A 2 III B(O) 6 MRM neo-adjchemo PRE
42 PITCHAIAMMAL 4 51 F 31335 L T2 N1 M0 A 1 II 2 MRM POST
43 MUTHUMANICKAM 4 60 F 33832 L T4b N2 M1 B 3 IV 8 Pal. Mast + chemo  RT POST
44 SURIYAL BEGAM 2 36 F 31335 R
T3 N1 M0
A 2 III A 3 MRM Chemo RT & hormona PRE
45 PALANIAMMAL 4 55 F 30989 R
T4b N3c M0
B 2 III B(I) 7 Neo-adj-->pal.mast-->Chemo POST
46 MURUGAMMAL 2 33 F 21752 L T2 N1 M0 A 1 II 2 MRM PRE
47 ROOTH 3 50 F 20629 L T3 N1 M0 A 2 III A 3 MRM --->Chemo & RT POST
48 PAPPA 4 60 F 5627 R T2 N1 M0 A 1 II 2 MRM POST
49 VALLI 4 58 F 90134 L T2 N0 M0 A 1 I 1 MRM --->Chemo POST
50 SIKKANDER BEEVI 2 40 F 6614 R
T4b N2 M0
A 2 III B(O) 6
Neo-adj-Chemo-->MRM 
Chemo RT & hormona PRE
51 GANDHI 2 36 F 6644 R T3 N1 M0 A 2 III A 3 MRM PRE
52 AROCKIA SELVI 3 45 F 6928 R T2 N1 M0 A 1 II 2 MRM PRE
53 SETHULAXMI 4 53 F 4352 L T3 N1 M0 A 2 III A 3 MRM POST
54 MARI 4 55 F 105070 L T3 N1 M0 A 2 III A 3 MRM POST
55 ARPUTHAM 4 60 F 100654 L
T4b N2 M0
B 2 III B(I) 7
Neo adj chmo -->NR --> 
Pal.chemo RT POST
S.No Name AGE GROUP Age Sex IP No Side TNM Stage O/IO
TYPE 
OF BC STAGE Treatment given
Menopausal 
statusStaging
56 PARAMEESHWARI 4 56 F 99154 R T3 N1 M0 A 2 III A 3 MRM --> adj chemo RT POST
57 VASANTHA 2 40 F 98411 R T2 N1 M0 A 1 II 2 MRM PRE
58 ARIVUKALANGIAM 3 43 F 98654 R T3 N1 M0 A 2 III A 3 MRM--> chemo RT PRE
59 JEYALAKSHMI 2 34 F 93248 R T2 N1 M0 A 1 II 2 MRM PRE
60 SOUNDARAM 4 60 F 85002 L T3 N1 M0 A 2 III A 3 MRM--> chemo RT POST
61 LALITHA 1 27 F 90384 L Tx N0 M0 A 1 I 1 MRM--> chemo PRE
62 PARVATHI 3 50 F 86469 L T3 N2 M0 A 2 III A(IO)-->O 4 MRM PRE
63 KALIAMMAL 3 50 F 80844 L T2 N1 M0 A 1 II 2 MRM POST
64 PITCHAIAMMAL 5 65 F 79616 R
T4b N3c M0
B 2 II B(I) 7
Neo adj chemo -->NR -->Pal. 
Mast POST
65 ATHAYEE 3 48 F 84649 L T2 N1 M0 A 1 II 2 MRM PRE
66 PIDARI 4 59 F 30867 L T3 N1 M0 A 2 III A 3 MRM -->chemo RT POST
67 KALIAMMAL 2 35 F 80502 R T3 N1 M0 A 2 III A 3 MRM -->chemo RT PRE
68 VALLI 3 45 F 77714 R T2 N1 M0 A 1 II 2 MRM PRE
69 CHINNIAMMAL 2 37 F 77613 R T1 N1 M0 A 1 II 2 MRM PRE
70 KANNIAMMAL 5 70 F 75811 L T3 N1 M0 A 2 III A 3 MRM -->chemo RT POST
71 REVATHY 4 55 F 76916 R T2 N1 M0 A 1 II 2 MRM POST
72 RAIYA BANU 2 32 F 70011 R
T4b N2 M0 A 2 III B(O) 6
Neo adj chemo -->MRM --> 
chemo +RT PRE
73 LAKSHMI 4 57 F 70111 L T2 N1 M0 A 1 II 2 MRM POST
74 ANTHONIAMMAL 2 40 F 66352 L T3 N2 M0 A 2 III A(IO)-->O 4 MRM PRE
75 VASANTHI 2 33 F 67825 L Tx N0 M0 A 1 I 1 MRM PRE
76 JAYAKODI 3 45 F 71462 L
T3 N1 M0
A 2 III A 3 MRM -->chemo+RT+hormona PRE
77 RAJAMMAL 5 63 F 68889 R T2 N1 M0 A 1 II 2 MRM POST
78 VASANTHA 2 33 F 67825 L T3 N1 M0 A 2 III A 3 MRM -->chemo+RT+hormona PRE
79 DHANUSKODI 2 40 F 65740 L
T4b N2 M0
A 2 III B(O) 6
Neo adj chemo-->MRM--
>C+RT PRE
80 MURUGESHWARI 1 30 F 63675 R
T3 N1 M0
A 2 III A 3 MRM -->chemo+RT+hormona PRE
81 JEBALKUMARI HELENE 3 48 F 56849 L
T2 N1 M0 A 1 II 2 MRM PRE
82 PARVATHY 5 70 F 55507 R T4b N3c M1 B 3 IV 8 Pal.mast-->Chemo POST
S.No Name AGE GROUP Age Sex IP No Side TNM Stage O/IO
TYPE 
OF BC STAGE Treatment given
Menopausal 
statusStaging
83 KUPPAMMAL 3 45 F 47810 R T2 N1 M0 A 1 II 2 MRM PRE
84 NAGOMI 5 70 F 54770 R T3 N1 M0 A 2 III A 3 MRM -->chemo POST
85 INDRA 2 40 F 53430 L
T4c N2 M0 A 2 III B(O) 6
Neo adj chmo --> MRM --
>chemo RT PRE
86 VALLI 3 47 F 45422 L T2 N1 M0 A 1 II 2 MRM POST
87 SHANDHI 3 44 F 48896 R Tx N0 M0 A 1 I 1 MRM PRE
88 PARVATHY] 6 75 F 47803 L T3 N1 M0 A 2 III A 3 MRM --chemo RT POST
89 CHILLAIAMMAL 3 43 F 41797 R T2 N1 M0 A 1 II 2 MRM PRE
90 MUTHULAKSHMI' 3 50 F 45494 R T3 N1 M0 A 2 III A 3 MRM --chemo RT POST
91 AMINA 2 40 F 45495 R T2 N1 M0 A 1 II 2 MRM PRE
92 RENGANAYAKI 4 58 F 47933 R T3 N0 M0 A 1 II 2 MRM POST
93 ESWARI 2 40 F 46817 R
T4b N2 M0
A 2 III B(O) 6
Neo adj chemo -->MRM --> 
chemo +RT+ hormona PRE
94 KAMATCHI 4 55 F 41147 R T2 N1 M0 A 1 II 2 MRM POST
95 SHIVANAMMAL 3 50 F 38135 L T2 N1 M0 A 1 II 2 MRM POST
96 JEYARANI 3 45 F 38173 L
T3 N1 M0
A 2 III A 3 MRM --chemo RT+ hormona PRE
97 KUPPAMMAL 3 50 F 36731 R T2 N1 M0 A 1 II 2 MRM POST
98 MEENAL 3 50 F 29434 R T2 N1 M0 A 1 II 2 MRM POST
99 SUBBUTHAI 2 38 F 33283 R T3 N2 M0 A 2 III A(IO)-->O 4 MRM PRE
100 SUSEELA 4 52 F 34288 L T2 N1 M0 A 1 II 2 MRM POST
101 CHITHRA 2 31 F 33053 L Tx N0 M0 A 1 I 1 MRM PRE
102 INDRANI 3 48 F 26532 R
T4b N1 M0 A 2 III B(O) 6
Neo adj chemo -->MRM --> 
chemo +RT+ hormona PRE
103 MUNIAMMAL 3 50 F 29802 R T2 N1 M0 A 1 II 2 MRM POST
104 SELVI 1 29 F 27274 R Tx N0 M0 A 1 I 1 MRM PRE
105 BAMA 2 35 F 29069 R T3 N1 M0 A 2 III A 3 MRM --chemo RT+ hormona PRE
106 VELANKANNI 2 37 F 28373 R T3 N1 M0 A 2 III A 3 MRM --chemo RT+ hormona PRE
107 PALANIAMMAL 4 60 F 29171 R T2 N1 M0 A 1 II 2 MRM POST
108 DHANALAKSHMI 6 78 F 24517 L T4b N2 M1 B 3 IV 8 Pal.mast-->Chemo POST
109 JOTHIAMMAL 2 40 F 95259 L T2 N1 M0 A 1 II 2 Pal.mast-->Chemo PRE
S.No Name AGE GROUP Age Sex IP No Side TNM Stage O/IO
TYPE 
OF BC STAGE Treatment given
Menopausal 
statusStaging
110 PITCHAIMANI 3 41 F 97298 L
T3 N1 M0
A 2 III A 3 MRM --chemo RT+ hormona PRE
111 SAROJA 3 47 F 100889 R T3 N2 M0 A 2 III A(IO)-->O 4 MRM POST
112 USHA 2 35 F 20465 R T2 N1 M0 A 1 II 2 MRM PRE
113 LAXMI 5 68 F 20599 R T4b N2 M1 B 3 IV 8 Pal.mast-->Chemo POST
114 RAMU 4 58 F 91096 L T2 N1 M0 A 1 II 2 MRM POST
115 SUNDARI 4 60 F 101668 R T3 N1 M0 A 2 III A 3 MRM --chemo RT+ hormona POST
116 KAMALA 3 50 F 100896 L T2 N1 M0 A 1 II 2 MRM POST
117 POONGOTHAI 3 45 F 10344 R T2 N1 M0 A 1 II 2 MRM PRE
118 PERIYAKKAL 3 48 F 90171 L
T3 N1 M0 A 2 III A 3 MRM --chemo RT+ hormona PRE
119 JOTHI 4 59 F 90190 R
T3 N1 M0 A 2 III A 3 MRM --chemo RT+ hormona POST
120 PALANIAMMAL 3 45 F 91117 R T2 N1 M0 A 1 II 2 MRM PRE
121 VIJAYA 4 51 F 36872 L T3 N2 M0 A 2 III A(IO)-->O 4 MRM POST
122 GANTHIMATHI 5 65 F 70792 L T2 N1 M0 A 1 II 2 MRM POST
123 RAJAMMAL 3 42 F 76611 L T2 N1 M0 A 1 II 2 MRM PRE
124 VALLIAMMAL 5 66 F 76735 R T3 N1 M0 A 2 III A 3 MRM POST
125 MUTHUMARI 3 50 F 76353 L T3 N2 M0 A 2 III A(IO)-->O 4 MRM POST
126 KUMUDHAVALLI 1 26 F 76571 L Tx N0 M0 A 1 I 1 MRM PRE
127 AARAIJEE 3 45 F 76577 L
T3 N1 M0 A 2 III A 3 MRM --chemo RT+ hormona PRE
128 RAKKAMMAL 3 42 F 76590 R T2 N1 M0 A 1 II 2 MRM PRE
129 PITCHAIAMMAL 2 40 F 78860 R T2 N1 M0 A 1 II 2 MRM PRE
130 ANDAMMAL 3 45 F 78896 L T3 N3C M0 A 2 III B( IO) 3 PALLIATIVE  chemo RT PRE
131 RASAMMAL 2 40 F 84941 L Tx N0 M0 A 1 I 1 MRM PRE
132 ASNAMMAL 3 47 F 85743 B/L T4c N2 M1 B 3 IV 8 PALLIATIVE  chemo RT POST
133 RANJITHAM 4 55 F 83877 R T2 N1 M0 A 1 II 2 MRM POST
134 SHANTHI 4 52 F 89006 L
T3 N1 M0 A 2 III A 3 MRM --chemo RT+ hormona POST
135 CHITHRAJEE 5 65 F 87379 R
T3 N1 M0
A 2 III A 3 MRM --chemo RT+ hormona POST
136 KALAVATHY 2 32 F 87681 L Tx N0 M0 A 1 I 1 MRM PRE
S.No Name AGE GROUP Age Sex IP No Side TNM Stage O/IO
TYPE 
OF BC STAGE Treatment given
Menopausal 
statusStaging
137 LAXMI 4 55 F 95630 R
T3 N1 M0 A 2 III A 3 MRM --chemo RT+ hormona POST
138 SURYAGANDHI 5 65 F 97537 L T2 N1 M0 A 1 II 2 MRM POST
139 KUPPAMUTHU 2 40 F 610814 R T3 N2 M0 A 2 III A(IO)-->O 4 MRM PRE
140 KOWSALYA 3 50 F 20264 R T2 N1 M0 A 1 II 2 MRM POST
141 RANI 3 42 F 101443 L T2 N1 M0 A 1 II 2 MRM PRE
142 ARASAMMAL 2 40 F 25341 L
T3 N1 M0 A 2 III A 3 MRM --chemo RT+ hormona PRE
143 LAXMI PALANIYACHI 3 45 F 29515 L T2 N1 M0 A 1 II 2 MRM PRE
144 SANHARI 3 50 F 30734 R
T3 N1 M0 A 2 III A 3 MRM --chemo RT+ hormona POST
145 MANIAMMAL 4 58 F 30829 R T3 N1 M0 A 2 III A 3 MRM POST
146 SAVITHRI 4 60 F 25325 R T3 N2 M0 A 2 III A(IO)-->O 4 MRM POST
147 MAHABOOBA 3 44 F 32337 L T2 N1 M0 A 1 II 2 MRM PRE
148 MARUDHAYEE 4 60 F 33522 R T3 N1 M0 A 2 III A 3 MRM --chemo RT POST
149 AYYAMMAL 3 50 F 32138 R T3 N1 M0 A 2 III A 3 MRM --chemo RT POST
150 VELLAIAMMAL 3 45 F 32398 L T2 N1 M0 A 1 II 2 MRM PRE
151 PANDIAMMAL 4 60 F 37725 R T3 N1 M0 A 2 III A 3 MRM --chemo RT POST
152 ARASAMMAL 3 49 F 36862 B/L T3 N1 M0 A 2 III A 3 MRM POST
153 IRULAYEE 6 75 F 42416 R T3 N1 M0 A 2 III A 3 MRM --chemo RT POST
154 SOWDAMANI 5 69 F 39453 R T2 N1 M0 A 1 II 2 MRM POST
155 JATHIMUTHU 2 35 F 42117 R Tx N1 M0 A 1 I 1 MRM PRE
156 GANDHIMATHI 1 30 F 45387 R T3 N2 M0 A 2 III A(IO)-->O 4 MRM PRE
157 PANCHAVARNAM 2 40 F 46765 L T4c N2 M1 B 3 IV 8 Pal.chemo + hormona PRE
158 AMUTHARANI 2 35 F 49721 L T4b N3c M1 B 3 IV 8 Pal.mast-->Chemo PRE
159 SARASWATHY 4 52 F 48112 R T2 N1 M0 A 1 II 2 MRM POST
160 MARIAMMAL 4 55 F 49620 L T4c N3c M1 B 3 IV 8 Pal.chemo POST
161 SHERINA BANU 3 48 F 52133 R T2 N1 M0 A 1 II 2 MRM PRE
162 KAMARNISHA 3 45 F 49599 L T3 N1 M0 A 2 III A 3 Pal.chemo RT+ hormona PRE
163 VIJIYA 3 50 F 50917 R T2 N1 M0 A 1 II 2 MRM POST
164 MUMTAJ 3 45 F 49099 L
T4b N3c M0 B 2 III B(IO) 7
Neo adj chemo -->NR -->Pal. 
Mast+chemo RT PRE
S.No Name AGE GROUP Age Sex IP No Side TNM Stage O/IO
TYPE 
OF BC STAGE Treatment given
Menopausal 
statusStaging
165 KRISHNAMMAL 5 65 F 56910 R T2 N1 M0 A 1 II 2 MRM POST
166 MUTHUPILLAI 5 70 F 58906 R T3 N1 M0 A 2 III A 3 MRM POST
167 SIVABACKIAM 4 55 F 37689 L T2 N1 M0 A 1 II 2 MRM POST
168 FATHIMA 2 38 F 63450 L T3 N2 M0 A 2 III A(IO)-->O 4 MRM PRE
169 VASANTHI 4 55 F 59461 L T2 N1 M0 A 1 II 2 MRM POST
170 SARASWATHY 3 41 F 66434 L T2 N1 M0 A 1 II 2 MRM PRE
171 RANI 2 40 F 70671 L T3 N1 M0 A 2 III A 3 MRM -->chemo RT PRE
172 GOMU 3 42 F 69648 R T2 N1 M0 A 1 II 2 MRM PRE
173 FATHIMABEEVI 3 45 F 72314 R
T4b N3c M0 B 2 III B(I) 7
Neo adj chemo -->NR -->Pal. 
Mast+chemo RT PRE
174 VIJAYALAXMI 4 56 F 74199 L T4b N2 M1 B 3 IV 8 Pal.mast-->Chemo POST
175 POOHUMAYIL 2 40 F 70357 L T2 N1 M0 A 1 II 2 MRM PRE
176 JAMEELA 2 37 F 72800 L Tx N0 M0 A 1 I 1 MRM PRE
177 PARVATHY 3 45 F 78204 R T2 N1 M0 A 1 II 2 MRM PRE
178 VELAMMAL 4 58 F 80237 R T3 N2 M0 A 2 III A(IO)-->O 4 MRM POST
179 REKHA 1 30 F 71086 R Tx N0 M0 A 1 I 1 MRM PRE
180 CHITHRADEVI 1 28 F 79969 R
T4b N2 M0 B 2 III B(I) 7
Neo adj chemo -->NR --
>proueceboe Pal. Mast PRE
181 DHANALAKSHMI 2 37 F 82857 R T2 N1 M0 A 1 II 2 MRM PRE
182 MUTHULAXMI 4 57 F 82836 L T3 N1 M0 A 2 III A 3 MRM -->chemo RT POST
183 SIVAKAMI 4 52 F 83951 R T2 N1 M0 A 1 II 2 MRM POST
184 SOUNDARAM 2 40 F 85002 L T3 N2 M0 A 2 III A(IO)-->O 4 MRM PRE
185 INDRA 2 37 F 89260 L Tx N0 M0 A 1 I 1 MRM PRE
186 THILAGAVATHI 3 49 F 92087 L
T4b N3 M0 B 2 III B(IO) 7
Neo adj chemo -->NR -->Pal. 
Mast PRE
187 PANCHU 2 37 F 92090 L Tx N0 M0 A 1 I 1 MRM PRE
188 PITCHAIAMMAL 3 48 F 92007 R T2 N1 M0 A 1 II 2 MRM PRE
189 TAMILSELVI 2 40 F 97916 R
T4b N3c M0
B 2 III B(I) 7
Neo adj chemo -->NR -->Pal. 
Mast PRE
190 MEENAKSHI 2 38 F 94783 L
T4b N2 M0
B 2 III B(I) 7
Neo adj chemo -->NR -->Pal. 
Mast PRE
191 LAKSHMI 1 25 F 10147 R Tx N0 M0 A 1 I 1 MRM PRE
S.No Name AGE GROUP Age Sex IP No Side TNM Stage O/IO
TYPE 
OF BC STAGE Treatment given
Menopausal 
statusStaging
192 BOOMA 2 35 F 103831 L T3 N2 M0 A 2 III A(IO)-->O 4 MRM PRE
193 JAYANTHI 3 42 F 106681 R T2 N1 M0 A 1 II 2 MRM PRE
194 SYED ROHIA 1 29 F 105675 L T3 N2 M0 A 2 III A(IO)-->O 4 MRM PRE
195 SHANTHI 2 36 F 105361 L T2 N1 M0 A 1 II 2 MRM PRE
196 USHARANI 2 36 F 8796 L T2 N1 M0 A 1 II 2 MRM PRE
197 RAKKAMMAL 2 40 F 9052 R
T3 N1 M0 A 2 III A 3 MRM -->chemo RT+Hormonal PRE
198 SULTHANOMMAL 3 50 F 97184 R T4c N3c M0 B 3 IV 8 pal. chemo POST
199 EDANI 5 65 F 20986 L T3 N1 M0 A 2 III A 3 MRM -->chemo RT POST
200 PONMUDI 5 70 F 20901 R T2 N1 M0 A 1 II 2 MRM POST
201 PUSPAM 2 40 F 24631 L T2 N1 M0 A 1 II 2 MRM PRE
202 CHINNAPONNU 2 35 F 26453 R
T4b N3c M1 B 3 IV 8 Pal.mast-->Chemo+hormonal PRE
203 NAGAMMAL 4 60 F 23613 R T2 N1 M0 A 1 II 2 MRM POST
204 LAKSHMI 5 70 F 26790 L T3 N2 M0 A 2 III A(IO)-->O 4 MRM POST
205 THEIVANAI 2 35 F 26564 R T2 N1 M0 A 1 II 2 MRM PRE
206 MUTHUPILLAI 3 50 F 33478 R T3 N1 M0 A 2 III A 3 MRM -->chemo RT POST
207 KARUPAYEE 4 60 F 30395 L T2 N1 M0 A 1 II 2 MRM POST
208 VELAMMAL 4 60 F 35186 R T2 N1 M0 A 1 II 2 MRM POST
209 JEBAKANI 2 35 F 36199 L Tx N0 M0 A 1 I 1 MRM PRE
210 SUDHA 1 30 F 34433 L T3 N2 M0 A 2 III A(IO)-->O 4 MRM PRE
211 VAIRAKKAL 5 65 F 34204 R T2 N1 M0 A 1 I 1 MRM PRE
212 MALLIGA 4 56 F 20091 L T3 N1 M0 A 2 III A 3 MRM -->chemo RT POST
213 BOOMADEVI 3 45 F 4252 L T2 N1 M0 A 1 II 2 MRM PRE
214 INDIRA 3 45 F 47671 L T3 N1 M0 A 2 III A 3 MRM -->chemo RT PRE
215 SARASWATHY 2 32 F 47762 R Tx N0 M0 A 1 I 1 MRM PRE
216 GURUVAMMAL 3 43 F 56422 R T2 N1 M0 A 1 II 2 MRM PRE
217 PANDIAMMAL 1 30 F 49719 L T2 N1 M0 A 1 II 2 MRM PRE
218 RATHINAMMAL 5 65 F 54861 L T3 N2 M0 A 2 III A(IO)-->O 4 MRM POST
219 SUSEELA 2 39 F 57660 R T3 N2 M0 A 2 III A(IO)-->O 4 MRM PRE
S.No Name AGE GROUP Age Sex IP No Side TNM Stage O/IO
TYPE 
OF BC STAGE Treatment given
Menopausal 
statusStaging
220 KALIAMMAL 4 57 F 60891 L T3 N1 M0 A 2 III A 3 MRM -->chemo RT POST
221 SORNAMMAL 3 43 F 68027 R T3 N1 M0 A 2 III A 3 MRM -->chemo RT POST
222 TAMILSELVI 2 39 F 75288 R Tx N0 M0 A 1 I 1 MRM PRE
223 NAGAMMAL 4 60 F 73641 L T3 N2 M0 B 2 III A(IO) 5 MRM POST
224 PALANIAMMAL 2 40 F 64447 L T2 N1 M0 A 1 II 2 MRM PRE
225 MEHIRA  BEGAM 2 32 F 67858 R T3 N1 M0 A 2 III A 3 MRM -->chemo RT PRE
226 NEELA 2 40 F 65452 L T2 N1 M0 A 1 II 2 MRM PRE
227 SELVI 2 38 F 70287 R Tx N0 M0 A 1 I 1 MRM PRE
228 PADMAVATHI 5 65 F 62379 R T2 N1 M0 A 1 II 2 MRM POST
229 VELLIYAMMAL 5 63 F 67500 L T3 N1 M0 A 2 III A 3 MRM -->chemo RT POST
230 ALAGI 3 50 F 69146 R T3 N1 M0 A 2 III A 3 MRM -->chemo RT PRE
231 MARIAMMAL 5 62 F 66648 R T2 N1 M0 A 1 II 2 MRM POST
232 MALLIGA 3 50 F 68989 R T3 N1 M0 A 2 III A 3 MRM -->chemo RT POST
233 AMEENA BEEVI 3 50 F 66675 L T2 N1 M0 A 1 II 2 MRM POST
234 MAYAMMAL 3 50 F 70312 L T3 N2 M0 B 2 III A(IO) 5 MRM POST
235 KRISHNAMMAL 4 60 F 68021 R T3 N2 M0 A 2 III A(IO)-->O 4 MRM POST
236 AMARAVATHY 4 60 F 69975 R T3 N1 M0 A 2 III A 3 MRM POST
237 SIVAKAMI 2 40 F 69962 R T2 N1 M0 A 1 II 2 MRM PRE
238 KUPPATHAL 3 46 F 32106 R T2 N1 M0 A 1 II 2 MRM PRE
239 JOTHI 1 30 F 36222 L Tx N0 M0 A 1 I 1 MRM PRE
240 MAHESWARI 1 29 F 3819 L
T3 N1 M0 A 2 III A 3 MRM -->chemo RT+Hormonal PRE
241 MARUTHU 3 50 F 45580 L Tx N0 M0 A 1 I 1 MRM POST
242 JHANSI RANI 3 46 F 40102 L T3 N1 M0 A 2 III A 3 MRM -->chemo RT PRE
243 SHENBAGAVALLI 4 55 F 60084 R T N2 M0 A 2 III A(IO)-->O 4 MRM POST
244 VALLIAMMAL 3 47 F 59885 L T2 N1 M0 A 1 II 2 MRM PRE
245 SUBBULAXMI 1 30 F 666737 L
T3 N1 M0
A 2 III A 3 MRM -->chemo RT+Hormonal PRE
246 ROOPA 2 34 F 77892 L Tx N0 M0 A 1 I 1 MRM PRE
247 MOOKAYEE 2 40 F 416 L T3 N3c M1 B 3 IV 8 Pal.chemo RT+Hormonal PRE
S.No Name AGE GROUP Age Sex IP No Side TNM Stage O/IO
TYPE 
OF BC STAGE Treatment given
Menopausal 
statusStaging
248 RASIYABANU 2 32 F 1880 R T4b N3 M0 B 2 III B(IO) 7 Pal.chemo PRE
249 GOMATHY 2 40 F 4613 R T4c N3 M0 B 2 III B(IO) 7 Pal.chemo PRE
250 PARVATHY 6 75 F 6950 R T4c N2 M1 B 3 IV 8 Palliative chemo POST
251 PANJAVARNAM 2 40 F 8569 L T2 N1 M0 A 1 II 2 MRM PRE
252 RASIYA 4 60 F 9947 L T4b N3c M1 B 3 IV 8 Palliative chemo POST
253 ARUVAGAM 1 30 F 24044 L T4c N2 M0 B 2 III B(I) 7 Pal.chemo PRE
254 SAVITHRI 6 74 F 26446 L T4b N3c M1 B 3 IV 8 Palliative POST
255 KADHAR BEEVI 2 40 F 31683 L T4b N3c M0 B 2 III B(I) 7 palliative chemo PRE
256 IRULAYEE 1 30 F 33641 L T4b N2 M1 B 3 IV 8 palliative chemo PRE
257 ALAGI 4 55 F 41454 R T4b N3c M0 B 2 III B(IO) 7 Palliative chemo POST
258 THEDASELVAM 3 47 F 44025 L
T4b N2 M0 A 2 III B(O) 6
Neo adj chemo RT --> MRM --
> chemo RT PRE
259 PANCHAVARNAM 2 35 F 55153 L T4b N2 M0 B 3 IV 8 Toilet. mast PRE
260 GOMATHY 2 40 F 20407 L T4b N3c M1 B 3 IV 8 Toilet. mast PRE
261 DEIVANAI 5 63 F 46247 R T4b N3c M1 B 3 IV 8 Toilet. mast POST
262 ANNAMALAIAMMAL 5 70 F 44331 R T4b N2 M1 B 3 IV 8 Toilet. mast POST
263 PALANIAMMAL 3 50 F 33253 R T4b N2 M1 B 3 IV 8 Pal.mast POST
264 GNANAMANI 4 60 F 99099 R T4b N2 M1 B 3 IV 8 Pal.mast POST
265 ALAGI 1 21 F 50800 R T4b N2 M1 B 3 IV 8 Pal.chemo PRE
266 SARASWATHY 3 50 F 78176 L T4c N2 M1 B 3 IV 8 Pal.chemo POST
267 KARUPAYEE 4 60 F 107148 R T4b N3c M1 B 3 IV 8 Pal.chemo POST
268 KANNAKI 3 43 F 102935 R T4b N2 M1 B 3 IV 8 Pal.chemo PRE
269 SURYAGANDHI 3 50 F 101604 L T4c N2 M1 B 3 IV 8 Pal.chemo POST
270 MOOKAYEE 2 40 F 98090 L T4b N3c M1 B 3 IV 8 Pal.chemo PRE
271 ARAYAMMAL 2 40 F 96735 R T3 N3c M1 B 3 IV 8 Pal.chemo PRE
272 INDRANI 3 48 F 86755 L T2 N2 M1 B 3 IV 8 Pal.chemo PRE
273 MARIAMMAL 4 60 F 72301 L T3 N3c M1 B 3 IV 8 Pal.chemo POST
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PROFORMA 
Name  :      IP No. : 
Age   :      Address : 
Sex  :      Occupation : 
DOA  :      DOD  : 
Presentation : 
Complaints   : 
 Lump in the breast 
 Nipple discharge 
 Nipple retraction 
 Pain 
 Ulcer / nodule 
 Swelling in the axilla 
 Cough dyspnoea, chest pain 
 Bony pain 
 Anorexia, jaundice 
 Loss of weight 
Past History : 
 H/o previous surgery in the breast 
 H/o OCPs intake and HRT intake 
Personal H :   Diet     O/E  Anaemia 
Age at Menarche       PR - 
Menstrual  H    :     BP - 
Age at marriage   :     CVS - 
Age at 1st child birth  :     RS   - 
No. of Children     : 
Duration of breast feeding: 
Family History   : 
Examination : 
 Size, nipple retraction, nipple discharge, peau – d- orange, 
  Ulcer / nodule 
 Fixity to underlying structures 
 Nodal status 
 Bony tenderness 
 Hepatomegaly 
 Ascites 
 Pleural effusion 
Diagnosis and Stage : 
 Investigation : 
  Biopsy 
  Chest X ray 
  USG abdomen 
  Bone Scan 
Management : 
 Surgery 
   Neoadjuvant Æ Response 
 Chemo Adjuvant   
   Neo adjuvant Æ Response 
 RT  Adjuvant 
